Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and ...

The biotech sector, tracked by iShares Biotechnology ETF, rallied 40% in six months on rising M&A activity, still below ...

Biotech Insiders Are Spending Billions. Trump Favors Less Oversight. One Biotech ETF Could Ride the Surge. The SPDR S&P ...

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded ...

On November 14, 2025, Bain Capital Life Sciences Investors, LLC, disclosed a full exit from Nuvalent ( NUVL +3.29%), reducing ...

The State Street SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. What Are ...

Intellia Therapeutics pauses Nex-z gene-editing trial after participant death. Click here for my updated look at NTLA stock ...

For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week high and rose 73.06% from its 52-week low price of $66.66/share. But, are ...

Cathie Wood’s ARK ETF published their daily trades for Tuesday, November 18, 2025, showcasing significant activity in several notable stocks. The largest transaction of the day was the purchase of ...

The healthcare sector was a contrarian pick for SoFi's Liz Thomas this year, that could come into its own in 2026. Year-end angst just keeps hitting investors, with no signs of dip-buying after Monday ...